Boehringer Ingelheim has announced the appointment of Christoph Tautphaeus as head of animal health Australia and New Zealand, succeeding Daniel Watkins who has been promoted to vice president, pets in the United States.
Mr Tautphaeus is currently the head of finance and administration for Boehringer Ingelheim Australia and New Zealand and will commence his new role 1 July 2023.
Mr Watkins has led Boehringer’s animal health division in Australia and New Zealand since January 2022 and been with Boehringer Ingelheim since 2012.
He also served as a director of Animal Medicines Australia, the peak industry body representing the leaders of the animal health industry in Australia.
"Daniel has been an integral part of our team as Head of Animal Health. He has captained with integrity and vision and his promotion to the world’s largest pet market is testament to his successful leadership here," said Dirk Otto, General Manager, Boehringer Ingelheim Australia and New Zealand.
“I thank Daniel for his invaluable contributions, and I wish him all the best in his new US role.
“Christoph Tautphaeus will succeed Daniel as head of animal health Australia and New Zealand, ensuring a seamless transition as the baton is passed into safe and trusted hands,” Mr Otto said.
“Christoph has been with Boehringer Ingelheim since 2008, where he has led various teams and departments across Germany, Denmark and Asia Pacific, prior to taking his current head of finance Australia and New Zealand position in 2018.
“Christoph holds postgraduate and Honours degrees in Business Administration and International Business from United Kingdom and German universities.
“Christoph joins the Australia and New Zealand animal health team that is strategically focused and united,” Mr Otto said. “The business is looking ahead to an exciting period defined by innovative new product launches, strong technical leadership, and an unwavering customer focus.”
Mr Tautphaeus said he was excited to step into such an energised animal health team.
“This business leadership opportunity reaffirms my great respect for Boehringer Ingelheim as an organisation dedicated to its people, and I look forward to working with my new team and our valued customers and industry partners to transform lives and deliver better health to animals across Australia and New Zealand.”
